BENZNIDAZOLE
PeakSMbenznidazole
NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
BENZNIDAZOLE (benznidazole) is [see microbiology ( )] . First approved in 2017.
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Benznidazole is an oral tablet antiparasitic agent approved in 2017 for the treatment of American trypanosomiasis (Chagas disease), a neglected tropical disease caused by Trypanosoma cruzi. The drug works through a mechanism that disrupts parasite DNA and protein synthesis. It represents a critical therapeutic option for patients in endemic regions across Central and South America.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30%), suggesting stable but not high-growth commercial environment with specialized team needs.
Mechanism of Action
[see Microbiology ( )] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on benznidazole offers a specialized career path in neglected tropical disease therapeutics with focus on emerging market expertise and global health impact. The role demands strong commercial acumen in endemic region strategies and medical affairs capabilities to support niche patient populations.
Field Sales RepresentativeBrand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.